These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Hyperdynamic microtubules, cognitive deficits, and pathology are improved in tau transgenic mice with low doses of the microtubule-stabilizing agent BMS-241027. Barten DM; Fanara P; Andorfer C; Hoque N; Wong PY; Husted KH; Cadelina GW; Decarr LB; Yang L; Liu V; Fessler C; Protassio J; Riff T; Turner H; Janus CG; Sankaranarayanan S; Polson C; Meredith JE; Gray G; Hanna A; Olson RE; Kim SH; Vite GD; Lee FY; Albright CF J Neurosci; 2012 May; 32(21):7137-45. PubMed ID: 22623658 [TBL] [Abstract][Full Text] [Related]
5. Short Fibrils Constitute the Major Species of Seed-Competent Tau in the Brains of Mice Transgenic for Human P301S Tau. Jackson SJ; Kerridge C; Cooper J; Cavallini A; Falcon B; Cella CV; Landi A; Szekeres PG; Murray TK; Ahmed Z; Goedert M; Hutton M; O'Neill MJ; Bose S J Neurosci; 2016 Jan; 36(3):762-72. PubMed ID: 26791207 [TBL] [Abstract][Full Text] [Related]
6. Prevention of tau seeding and propagation by immunotherapy with a central tau epitope antibody. Albert M; Mairet-Coello G; Danis C; Lieger S; Caillierez R; Carrier S; Skrobala E; Landrieu I; Michel A; Schmitt M; Citron M; Downey P; Courade JP; Buée L; Colin M Brain; 2019 Jun; 142(6):1736-1750. PubMed ID: 31038156 [TBL] [Abstract][Full Text] [Related]
7. Tau pathology is present in vivo and develops in vitro in sensory neurons from human P301S tau transgenic mice: a system for screening drugs against tauopathies. Mellone M; Kestoras D; Andrews MR; Dassie E; Crowther RA; Stokin GB; Tinsley J; Horne G; Goedert M; Tolkovsky AM; Spillantini MG J Neurosci; 2013 Nov; 33(46):18175-89. PubMed ID: 24227726 [TBL] [Abstract][Full Text] [Related]
8. GFP-Mutant Human Tau Transgenic Mice Develop Tauopathy Following CNS Injections of Alzheimer's Brain-Derived Pathological Tau or Synthetic Mutant Human Tau Fibrils. Gibbons GS; Banks RA; Kim B; Xu H; Changolkar L; Leight SN; Riddle DM; Li C; Gathagan RJ; Brown HJ; Zhang B; Trojanowski JQ; Lee VM J Neurosci; 2017 Nov; 37(47):11485-11494. PubMed ID: 28986461 [TBL] [Abstract][Full Text] [Related]
9. Tau exhibits unique seeding properties in globular glial tauopathy. Chung DC; Carlomagno Y; Cook CN; Jansen-West K; Daughrity L; Lewis-Tuffin LJ; Castanedes-Casey M; DeTure M; Dickson DW; Petrucelli L Acta Neuropathol Commun; 2019 Mar; 7(1):36. PubMed ID: 30845985 [TBL] [Abstract][Full Text] [Related]
10. Conformation determines the seeding potencies of native and recombinant Tau aggregates. Falcon B; Cavallini A; Angers R; Glover S; Murray TK; Barnham L; Jackson S; O'Neill MJ; Isaacs AM; Hutton ML; Szekeres PG; Goedert M; Bose S J Biol Chem; 2015 Jan; 290(2):1049-65. PubMed ID: 25406315 [TBL] [Abstract][Full Text] [Related]
11. Characterization of tau prion seeding activity and strains from formaldehyde-fixed tissue. Kaufman SK; Thomas TL; Del Tredici K; Braak H; Diamond MI Acta Neuropathol Commun; 2017 Jun; 5(1):41. PubMed ID: 28587664 [TBL] [Abstract][Full Text] [Related]
12. Vectored Intracerebral Immunization with the Anti-Tau Monoclonal Antibody PHF1 Markedly Reduces Tau Pathology in Mutant Tau Transgenic Mice. Liu W; Zhao L; Blackman B; Parmar M; Wong MY; Woo T; Yu F; Chiuchiolo MJ; Sondhi D; Kaminsky SM; Crystal RG; Paul SM J Neurosci; 2016 Dec; 36(49):12425-12435. PubMed ID: 27927959 [TBL] [Abstract][Full Text] [Related]
13. Highly Specific and Sensitive Target Binding by the Humanized pS396-Tau Antibody hC10.2 Across a Wide Spectrum of Alzheimer's Disease and Primary Tauopathy Postmortem Brains. Helboe L; Rosenqvist N; Volbracht C; Pedersen LØ; Pedersen JT; Christensen S; Egebjerg J; Christoffersen CT; Bang-Andersen B; Beach TG; Serrano GE; Falsig J J Alzheimers Dis; 2022; 88(1):207-228. PubMed ID: 35570492 [TBL] [Abstract][Full Text] [Related]
14. Tau passive immunization blocks seeding and spread of Alzheimer hyperphosphorylated Tau-induced pathology in 3 × Tg-AD mice. Dai CL; Hu W; Tung YC; Liu F; Gong CX; Iqbal K Alzheimers Res Ther; 2018 Jan; 10(1):13. PubMed ID: 29386065 [TBL] [Abstract][Full Text] [Related]
15. Resveratrol Rescues Tau-Induced Cognitive Deficits and Neuropathology in a Mouse Model of Tauopathy. Sun XY; Dong QX; Zhu J; Sun X; Zhang LF; Qiu M; Yu XL; Liu RT Curr Alzheimer Res; 2019; 16(8):710-722. PubMed ID: 31368873 [TBL] [Abstract][Full Text] [Related]
16. Complement C3a receptor antagonist alleviates tau pathology and ameliorates cognitive deficits in P301S mice. Yao Y; Chang Y; Li S; Zhu J; Wu Y; Jiang X; Li L; Liu R; Ma R; Li G Brain Res Bull; 2023 Aug; 200():110685. PubMed ID: 37330021 [TBL] [Abstract][Full Text] [Related]
17. Specific targeting of tau oligomers in Htau mice prevents cognitive impairment and tau toxicity following injection with brain-derived tau oligomeric seeds. Castillo-Carranza DL; Gerson JE; Sengupta U; Guerrero-Muñoz MJ; Lasagna-Reeves CA; Kayed R J Alzheimers Dis; 2014; 40 Suppl 1():S97-S111. PubMed ID: 24603946 [TBL] [Abstract][Full Text] [Related]
18. Nasal tau immunotherapy clears intracellular tau pathology and improves cognitive functions in aged tauopathy mice. Gaikwad S; Puangmalai N; Sonawane M; Montalbano M; Price R; Iyer MS; Ray A; Moreno S; Kayed R Sci Transl Med; 2024 Jul; 16(754):eadj5958. PubMed ID: 38959324 [TBL] [Abstract][Full Text] [Related]
19. Proteopathic tau seeding predicts tauopathy in vivo. Holmes BB; Furman JL; Mahan TE; Yamasaki TR; Mirbaha H; Eades WC; Belaygorod L; Cairns NJ; Holtzman DM; Diamond MI Proc Natl Acad Sci U S A; 2014 Oct; 111(41):E4376-85. PubMed ID: 25261551 [TBL] [Abstract][Full Text] [Related]
20. Tau antibody 77G7 targeting microtubule binding domain suppresses proteopathic tau to seed tau aggregation. Li L; Miao J; Chu D; Jin N; Tung YC; Dai CL; Hu W; Gong CX; Iqbal K; Liu F CNS Neurosci Ther; 2022 Dec; 28(12):2245-2259. PubMed ID: 36114722 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]